---
topic: PSA Kinetics and Prostate Risk
tags: [urology, psa, prostate, cancer-screening, psa-velocity, mri]
priority: monitor
last_updated: 2026-05-03
confidence: medium-high
abstract: >-
  PSA is a follow-up signal, not an emergency branch. Current AUA/SUO and EAU guidance
  supports confirming a newly elevated/borderline PSA under standardized conditions before
  biomarkers, MRI, or biopsy; PSA velocity should not be used alone. If the repeat stays
  near/above 3 ug/L or risk markers are concerning, use free/total PSA, DRE, risk calculator,
  prostate-volume/PSA-density, and urology/MRI rather than jumping straight to biopsy.
related_topics: [planned-blood-tests.md]
---

# PSA Kinetics & Prostate Risk

## Summary

The cloud doc records PSA 1.3 -> 1.5 -> 2.0 -> 2.85 ug/L across 2015-2026, with no urinary symptoms documented. This is close enough to work-up thresholds to repeat deliberately, but not a stand-alone cancer alarm.

AUA/SUO 2023 plus the 2026 amendment says repeat a newly elevated PSA before biomarkers, imaging, or biopsy, and do not use PSA velocity alone. EAU is more concrete for asymptomatic men: if PSA is 3-10 ng/mL and DRE is not suspicious, repeat after about 4 weeks; if it normalizes, resume interval follow-up.

## Standardized repeat

Order at Biomed: **PSA Total** ($10, 1 day). If this is meant to resolve the branch rather than just trend it, add **Free PSA / PSA Free** ($15, 1 day) at the same draw so percent-free PSA can be interpreted.

Before the draw:

- Use the same lab/assay when practical.
- Avoid ejaculation, vigorous cycling, prostate manipulation, and testing during UTI/prostatitis/fever.
- Do not treat one borderline result as a biopsy decision; biologic and lab variation are large enough that repeat testing changes management.

## Escalation table

| Repeat result / context | Meaning | Practical next step |
|---|---|---|
| PSA falls clearly toward prior baseline | Transient fluctuation more likely | Return to trend monitoring; avoid over-reading velocity. |
| PSA remains around 2.5-3.0 | Still borderline, not diagnostic | Calculate percent-free PSA if available; consider clinician DRE and risk calculator. |
| PSA rises above ~3.0 or keeps rising on standardized repeats | Work-up branch persists | Urology review is reasonable; add DRE, percent-free PSA, and prostate-volume context. |
| Low percent-free PSA, abnormal DRE, strong family/genetic risk, or concerning risk calculator | Higher risk of clinically significant cancer | Urology-led mpMRI before biopsy is the modern pathway when available. |
| MRI PI-RADS 3-5 or high PSA density | Lesion/volume-adjusted risk becomes material | Urology decides targeted/systematic biopsy; do not self-manage from PSA alone. |

## Interpretation boundaries

- **PSA velocity:** useful as background trend, but not a stand-alone escalation rule. AUA/SUO explicitly says not to use velocity alone for biomarkers, imaging, or biopsy; Vickers/ERSPC repeat-biopsy data found weak added discrimination.
- **Age-specific ranges:** treat them as rough context, not a hard reassurance rule. At age 51, the issue is that PSA is now near action thresholds and has risen, not that it crosses a universal cancer cutoff.
- **Percent-free PSA:** helps risk stratification when total PSA is borderline, but it is context, not a yes/no cancer test.
- **PSA density:** requires prostate volume from ultrasound or MRI; >0.15 ng/mL/cc is a commonly used concern threshold, while EAU now discusses higher thresholds such as 0.20 when MRI is negative.
- **DRE:** not a sole screening tool, but useful alongside PSA when the branch remains active.

## References

- AUA/SUO Early Detection Guideline Part I, 2023: PSA first, repeat newly elevated PSA, no PSA-velocity-only escalation, DRE/risk-calculator context. PMID: 37096582.
- AUA/SUO Part II and 2026 amendment: biomarkers/MRI/biopsy are for risk-stratified decisions focused on Grade Group 2+ disease. PMIDs: 37096575, 41744286.
- EAU Prostate Cancer Diagnostic Evaluation: repeat PSA under standardized conditions before further work-up in asymptomatic PSA 3-10 ng/mL with non-suspicious DRE. https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
- PSA velocity evidence: limited added value beyond PSA alone in ERSPC repeat-biopsy analysis. PMID: 20643434.
- Biomed Phnom Penh tariff checked 2026-05-03: PSA Total $10; Free PSA / PSA Free $15; both serum, 1-day turnaround.